Summary
Eli Lilly and Company reported a substantial increase in financial performance for the first quarter of 2026 compared to the same period in 2025. Revenue surged by 56% to $19.8 billion, driven by strong volume growth, particularly from Mounjaro and Zepbound. This significant top-line growth, coupled with a higher gross margin and reduced acquired in-process R&D charges, led to a remarkable 168% increase in net income to $7.4 billion and a 170% rise in diluted earnings per share to $8.26. The company's strategic investments in research and development continue, with R&D expenses increasing by 28% to support its robust pipeline. Despite increased operational costs, Lilly demonstrated impressive operational efficiency and profitability. The company also continued its share repurchase program, buying back $2.3 billion in stock during the quarter, indicating confidence in its financial health and commitment to shareholder returns.
Financial Highlights
44 data points| Revenue | $19.80B |
| Cost of Revenue | $3.58B |
| Gross Profit | $16.22B |
| SG&A Expenses | $2.93B |
| Net Income | $7.40B |
| EPS (Basic) | $8.27 |
| EPS (Diluted) | $8.26 |
| Shares Outstanding (Basic) | 894.50M |
| Shares Outstanding (Diluted) | 895.90M |
Key Highlights
- 1Revenue increased by 56% year-over-year to $19.8 billion, primarily driven by strong volume growth in Mounjaro and Zepbound.
- 2Net income more than doubled, rising 168% to $7.4 billion, reflecting improved gross margins and lower R&D acquisition charges.
- 3Diluted Earnings Per Share (EPS) saw a significant jump of 170% to $8.26.
- 4Research and Development expenses increased by 28% to $3.5 billion, indicating continued investment in pipeline development.
- 5The company repurchased $2.3 billion of its common stock during the quarter as part of its ongoing share repurchase program.
- 6Acquired IPR&D charges decreased significantly by 63% to $584 million, positively impacting profitability.
- 7The acquisition of Ventyx Biosciences for $1.1 billion was completed in March 2026, aimed at strengthening the inflammatory-mediated diseases portfolio.